Traws Pharma stock soars 200% on encouraging bird flu drug data

Shares of Traws Pharma Inc (NASDAQ: TRAW) more than tripled today after reporting encouraging early-stage data for its tivoxavir marboxil as a treatment of H5N1 bird flu. The investigational drug demonstrated safety and tolerability, and maintained blood levels above the EC90 for more than 23 days in a Phase I clinical trial. “Topline data for […]